Beta Drugs Limited

NSEI:BETA Stock Report

Market Cap: ₹21.6b

Beta Drugs Management

Management criteria checks 4/4

Beta Drugs' CEO is Rahul Batra, appointed in Jan 2021, has a tenure of 3.83 years. total yearly compensation is ₹12.10M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth ₹84.99M. The average tenure of the management team and the board of directors is 3.8 years and 7.3 years respectively.

Key information

Rahul Batra

Chief executive officer

₹12.1m

Total compensation

CEO salary percentage100.0%
CEO tenure3.8yrs
CEO ownership0.4%
Management average tenure3.8yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

CEO Compensation Analysis

How has Rahul Batra's remuneration changed compared to Beta Drugs's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹410m

Jun 30 2024n/an/a

₹387m

Mar 31 2024₹12m₹12m

₹364m

Dec 31 2023n/an/a

₹356m

Sep 30 2023n/an/a

₹348m

Jun 30 2023n/an/a

₹327m

Mar 31 2023₹12mn/a

₹307m

Dec 31 2022n/an/a

₹298m

Sep 30 2022n/an/a

₹289m

Jun 30 2022n/an/a

₹269m

Mar 31 2022₹8m₹8m

₹248m

Dec 31 2021n/an/a

₹216m

Sep 30 2021n/an/a

₹183m

Jun 30 2021n/an/a

₹150m

Mar 31 2021₹6m₹6m

₹117m

Dec 31 2020n/an/a

₹106m

Sep 30 2020n/an/a

₹95m

Jun 30 2020n/an/a

₹94m

Mar 31 2020₹5m₹5m

₹94m

Sep 30 2019n/an/a

₹97m

Jun 30 2019n/an/a

₹89m

Mar 31 2019₹1m₹1m

₹80m

Compensation vs Market: Rahul's total compensation ($USD143.26K) is about average for companies of similar size in the Indian market ($USD187.40K).

Compensation vs Earnings: Rahul's compensation has been consistent with company performance over the past year.

CEO

Rahul Batra (41 yo)

3.8yrs

Tenure

₹12,100,000

Compensation

Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...

Leadership Team

NamePositionTenureCompensationOwnership
Rahul Batra
Chairman & MD3.8yrs₹12.10m0.41%
₹ 89.1m
Varun Batra
Joint MD & Whole Time Director3.8yrs₹12.10m0.35%
₹ 74.7m
Nipun Arora
Chief Financial Officer3.7yrs₹3.10mno data
Rajni Brar
Company Secretary & Compliance Officer7.3yrs₹911.55kno data
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director5.7yrs₹5.12mno data
Seema Chopra
Whole Time Directorno data₹1.19mno data
Sanjeev Chopra
Vice President of Technicalno datano datano data

3.8yrs

Average Tenure

40.5yo

Average Age

Experienced Management: BETA's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rahul Batra
Chairman & MD10.3yrs₹12.10m0.41%
₹ 89.1m
Varun Batra
Joint MD & Whole Time Director10.3yrs₹12.10m0.35%
₹ 74.7m
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director2.8yrs₹5.12mno data
Seema Chopra
Whole Time Director5.3yrs₹1.19mno data
Manmohan Khanna
Independent Director7.3yrsno datano data
Rohit Parti
Independent Director7.3yrsno datano data

7.3yrs

Average Tenure

48yo

Average Age

Experienced Board: BETA's board of directors are considered experienced (7.3 years average tenure).